Testing effectiveness (Phase 2)Ended earlyNCT05441826
What this trial is testing
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Who this might be right for
Minimal Change DiseaseFocal Segmental Glomerulosclerosis
Tenet Medicines 1